Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 347,559 | 298,257 | 389,477 | 211,885 | 923,031 |
| Marketable Securities | 1,628,269 | 1,605,569 | 1,304,215 | 1,603,433 | 1,456,098 |
| Receivables | N/A | 25,000 | 200,000 | N/A | 305 |
| TOTAL | $1,985,671 | $1,937,132 | $1,908,078 | $1,853,026 | $2,417,513 |
| Non-Current Assets | |||||
| PPE Net | 115,851 | 134,093 | 151,945 | 163,634 | 137,575 |
| Investments And Advances | 0 | 0 | 1,973 | 53,130 | 0 |
| Intangibles | 0 | 0 | 16 | 71 | 125 |
| Other Non-Current Assets | 163,721 | 170,809 | 167,559 | 173,196 | 196,664 |
| TOTAL | $279,572 | $304,902 | $321,493 | $390,031 | $334,364 |
| Total Assets | $2,265,243 | $2,242,034 | $2,229,571 | $2,243,057 | $2,751,877 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,138 | 14,709 | 38,147 | 27,428 | 14,816 |
| Accrued Expenses | 90,520 | 41,523 | 45,773 | 77,817 | 91,727 |
| Other current liabilities | 13,113 | 10,417 | 5,141 | 20 | 171 |
| TOTAL | $149,120 | $87,782 | $108,791 | $121,107 | $119,883 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 15,771 | 3,845 | 4,105 | N/A | 1,011 |
| Other Non-Current Liabilities | 194,310 | 209,849 | 223,965 | 234,148 | 220,211 |
| TOTAL | $194,310 | $222,172 | $237,977 | $246,471 | $232,534 |
| Total Liabilities | $343,430 | $309,954 | $346,768 | $367,578 | $352,417 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 85,774 | 80,276 | 78,647 | 77,068 |
| Common Shares | 3,087 | 2,698 | 2,497 | 2,441 | 2,391 |
| Retained earnings | -1,947,551 | -1,365,952 | -999,700 | -846,090 | -195,915 |
| Other shareholders' equity | 4,761 | 1,778 | 1,851 | -15,710 | -5,130 |
| TOTAL | $1,921,813 | $1,932,080 | $1,882,803 | $1,875,479 | $2,399,460 |
| Total Liabilities And Equity | $2,265,243 | $2,242,034 | $2,229,571 | $2,243,057 | $2,751,877 |